Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer

IMPORTANCE: Although immune checkpoint inhibitors (ICIs), such as anti–PD-1 (programmed cell death 1) or anti–PD-L1 (programmed cell death 1 ligand 1), have proved effective in treating many cancers, patients receiving ICIs may experience immune-related adverse events (irAEs). Little evidence exists...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JAMA Oncol
Päätekijät: Simonaggio, Audrey, Michot, Jean Marie, Voisin, Anne Laure, Le Pavec, Jérome, Collins, Michael, Lallart, Audrey, Cengizalp, Geoffray, Vozy, Aurore, Laparra, Ariane, Varga, Andréa, Hollebecque, Antoine, Champiat, Stéphane, Marabelle, Aurélien, Massard, Christophe, Lambotte, Olivier
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Medical Association 2019
Aiheet:
Original Investigation
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6555478/
https://ncbi.nlm.nih.gov/pubmed/31169866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.1022
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia